SPIRACTIN

This brand name is authorized in Australia, New Zealand, South Africa

Active ingredients

The drug SPIRACTIN contains one active pharmaceutical ingredient (API):

1 Spironolactone UNII 27O7W4T232 - SPIRONOLACTONE

Spironolactone, as a competitive aldosterone antagonist, increases sodium excretion whilst reducing potassium loss at the distal renal tubule. It has a gradual and prolonged action. Read about Spironolactone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SPIRACTIN Tablet	Marketing Authorisation Holder	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C03DA01	Spironolactone	C Cardiovascular system → C03 Diuretics → C03D Potassium-sparing agents → C03DA Aldosterone antagonists
Discover more medicines within C03DA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2339D, 2340E
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 3035, 3036
Country: ZA	Health Products Regulatory Authority	Identifier(s): L/18.1/186, U/18.1/52